97 related articles for article (PubMed ID: 11233517)
1. Lamivudine for the treatment of chronic hepatitis B.
Dixon JS; Boehme RE
Acta Gastroenterol Belg; 2000; 63(4):348-56. PubMed ID: 11233517
[TBL] [Abstract][Full Text] [Related]
2. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
3. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
4. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol; 2002 Apr; 66(4):435-51. PubMed ID: 11857520
[TBL] [Abstract][Full Text] [Related]
6. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
7. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
8. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
9. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Sokal EM; Kelly DA; Mizerski J; Badia IB; Areias JA; Schwarz KB; Vegnente A; Little NR; Gardener SD; Jonas MM
Hepatology; 2006 Feb; 43(2):225-32. PubMed ID: 16440364
[TBL] [Abstract][Full Text] [Related]
10. Liver disease-significant improvement with lamivudine.
Leung N
J Med Virol; 2000 Jul; 61(3):380-5. PubMed ID: 10861650
[TBL] [Abstract][Full Text] [Related]
11. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
12. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
14. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
Chien RN; Liaw YF; Atkins M
Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
[TBL] [Abstract][Full Text] [Related]
15. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
16. [Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
Chang YJ; Yim JY; Cho NY; Choi CW; Baek SJ; Ahn SH; Choi DW; Kwon YD; Kim SS; Kwon OS; Kim JH; Yeon JE; Song JW; Byun KS; Lee CH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):397-404. PubMed ID: 12506244
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
[TBL] [Abstract][Full Text] [Related]
19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
20. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
